CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Increase (Decrease) in Contract with Customer, Liability
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Increase (Decrease) in Contract with Customer, Liability of $5.59 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-27 was $396.00K, a 96.84% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-28 was $5.20M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-27 was -$25.82M, a 620.77% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-27 was -$23.63M, a 534.92% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$38.14M, a 305.70% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $18.54M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$21.74M, a 137.71% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $57.66M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-27 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.59M 10-Q · filed 2026-08-05 | -$20.23M derived: sum of 3 quarters · filed 2026-08-05 | -$43.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $5.20M 10-Q · filed 2026-05-07 | -$20.62M derived: sum of 2 quarters · filed 2026-05-07 | -$44.25M derived: sum of 3 quarters · filed 2026-05-07 | -$31.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | -$25.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$49.45M derived: sum of 2 quarters · filed 2026-02-18 | -$36.93M derived: sum of 3 quarters · filed 2026-08-05 | -$38.14M 10-K · filed 2026-02-18 |
| 2025-09-27 | -$23.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$11.11M derived: sum of 2 quarters · filed 2026-08-05 | -$12.32M 10-Q · filed 2025-11-05 | -$7.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $12.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.31M 10-Q · filed 2026-08-05 | $16.26M derived: sum of 3 quarters · filed 2026-08-05 | $21.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$1.21M 10-Q · filed 2026-05-07 | $3.75M derived: sum of 2 quarters · filed 2026-05-07 | $9.18M derived: sum of 3 quarters · filed 2026-05-07 | -$2.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $10.39M derived: sum of 2 quarters · filed 2026-02-18 | -$1.42M derived: sum of 3 quarters · filed 2026-02-18 | $18.54M 10-K · filed 2026-02-18 |
| 2024-09-28 | $5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$6.37M derived: sum of 2 quarters · filed 2025-11-05 | $13.58M 10-Q · filed 2025-11-05 | $1.84M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | -$11.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.15M 10-Q · filed 2025-08-06 | -$3.60M derived: sum of 3 quarters · filed 2026-02-18 | -$6.80M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $19.96M 10-Q · filed 2025-05-07 | $8.21M derived: sum of 2 quarters · filed 2026-02-18 | $5.01M derived: sum of 3 quarters · filed 2026-02-18 | -$1.30M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | -$11.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$14.95M derived: sum of 2 quarters · filed 2026-02-18 | -$21.26M derived: sum of 3 quarters · filed 2026-02-18 | -$21.74M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$9.52M derived: sum of 2 quarters · filed 2024-11-06 | -$10.00M 10-Q · filed 2024-11-06 | -$5.90M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | -$6.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$6.80M 10-Q · filed 2024-08-07 | -$2.70M derived: sum of 3 quarters · filed 2025-02-19 | $23.22M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | -$481.00K 10-Q · filed 2024-05-09 | $3.61M derived: sum of 2 quarters · filed 2025-02-19 | $29.54M derived: sum of 3 quarters · filed 2025-02-19 | $45.10M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $30.02M derived: sum of 2 quarters · filed 2025-02-19 | $45.58M derived: sum of 3 quarters · filed 2025-02-19 | $57.66M 10-K · filed 2025-02-19 |
| 2022-09-24 | $25.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $41.49M derived: sum of 2 quarters · filed 2023-11-08 | $53.56M 10-Q · filed 2023-11-08 | $49.56M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $15.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $27.64M 10-Q · filed 2023-08-09 | $23.63M derived: sum of 3 quarters · filed 2024-02-14 | $13.74M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | $12.08M 10-Q · filed 2023-05-11 | $8.07M derived: sum of 2 quarters · filed 2024-02-14 | -$1.83M derived: sum of 3 quarters · filed 2024-02-14 | -$6.33M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$13.90M derived: sum of 2 quarters · filed 2024-02-14 | -$18.41M derived: sum of 3 quarters · filed 2024-02-14 | -$13.40M 10-K · filed 2024-02-14 |
| 2021-09-25 | -$9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$14.40M derived: sum of 2 quarters · filed 2022-11-02 | -$9.39M 10-Q · filed 2022-11-02 | $20.56M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | -$4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $502.00K 10-Q · filed 2022-08-03 | $30.46M derived: sum of 3 quarters · filed 2023-02-22 | $32.42M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $5.01M 10-Q · filed 2022-05-04 | $34.96M derived: sum of 2 quarters · filed 2023-02-22 | $36.93M derived: sum of 3 quarters · filed 2023-02-22 | $27.59M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $29.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $31.92M derived: sum of 2 quarters · filed 2023-02-22 | $22.58M derived: sum of 3 quarters · filed 2023-02-22 | $28.65M 10-K · filed 2023-02-22 |
| 2020-09-26 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$7.37M derived: sum of 2 quarters · filed 2021-11-03 | -$1.31M 10-Q · filed 2021-11-03 | -$3.37M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | -$9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$3.27M 10-Q · filed 2021-08-04 | -$5.34M derived: sum of 3 quarters · filed 2022-02-16 | -$6.65M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $6.07M 10-Q · filed 2021-05-04 | $4.00M derived: sum of 2 quarters · filed 2022-02-16 | $2.69M derived: sum of 3 quarters · filed 2022-02-16 | $16.85M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$3.38M derived: sum of 2 quarters · filed 2022-02-16 | $10.79M derived: sum of 3 quarters · filed 2022-02-16 | -$3.62M 10-K · filed 2022-02-16 |
| 2019-09-28 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $12.85M derived: sum of 2 quarters · filed 2020-10-29 | -$1.56M 10-Q · filed 2020-10-29 | $1.02M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | $14.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$241.00K 10-Q · filed 2020-08-05 | $2.34M derived: sum of 3 quarters · filed 2021-02-17 | $40.16M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | -$14.40M 10-Q · filed 2020-05-07 | -$11.82M derived: sum of 2 quarters · filed 2021-02-17 | $26.00M derived: sum of 3 quarters · filed 2021-02-17 | $39.96M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $40.40M derived: sum of 2 quarters · filed 2021-02-17 | $54.36M derived: sum of 3 quarters · filed 2021-02-17 | $36.07M 10-K · filed 2021-02-17 |
| 2018-09-29 | $37.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $51.78M derived: sum of 2 quarters · filed 2019-11-06 | $33.49M 10-Q · filed 2019-11-06 | $41.87M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | $13.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$4.33M 10-Q · filed 2019-07-31 | $4.05M derived: sum of 3 quarters · filed 2020-02-11 | -$6.54M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-03-31 | -$18.29M 10-Q · filed 2019-05-07 | -$9.91M derived: sum of 2 quarters · filed 2020-02-11 | -$20.50M derived: sum of 3 quarters · filed 2020-02-11 | |
| 2017-12-30 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | -$2.21M derived: sum of 2 quarters · filed 2020-02-11 | -$8.47M 10-K · filed 2020-02-11 | |
| 2017-09-30 | -$10.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$16.85M 10-Q · filed 2018-11-07 | ||
| 2017-07-01 | -$6.26M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $14.58M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |